<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Earnings</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Boston Sci’s Farapulse tops $1B in 2024, bright prospects for 2025</title>
      <description>
        <![CDATA[As pulsed field ablation transformed the electrophysiology market over the last year, Boston Scientific Corp. emerged as the biggest winner by far. In its fourth quarter earnings call on Wednesday, the company quantified just how successful its Farapulse PFA system has been.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716827</guid>
      <pubDate>Wed, 05 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716827-boston-scis-farapulse-tops-1b-in-2024-bright-prospects-for-2025</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/farawave-system-21oct24.webp?t=1729547834" type="image/jpeg" medium="image" fileSize="123935">
        <media:title type="plain">Farawave system</media:title>
        <media:description type="plain">Boston Scientific’s Farapulse system with Farawave Nav ablation catheter Credit: Boston Scientific Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>GE Healthcare beats earnings estimates in first year as standalone company</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[In its first full year since its spin-off from parent company General Electric Co., GE Healthcare Technologies Inc. reported beating Wall Street’s expectations. For 2023, revenues of $19.6 billion grew 8% organically vs. 2022.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705090</guid>
      <pubDate>Fri, 09 Feb 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705090-ge-healthcare-beats-earnings-estimates-in-first-year-as-standalone-company</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-symbol-with-arrow-graph-moving-up.webp?t=1701900511" type="image/jpeg" medium="image" fileSize="197116">
        <media:title type="plain">Dollar symbol with arrow graph</media:title>
      </media:content>
    </item>
    <item>
      <title>Boston Sci’s Farapulse approval intensifies PFA competition</title>
      <description>
        <![CDATA[  The U.S. FDA added a second pulsed field ablation (PFA) system to the approved list with its greenlight for Boston Scientific Corp.’s Farapulse for treatment of atrial fibrillation (AF). Farapulse joins Medtronic plc’s Pulseselect, which garnered FDA approval in December. Two other PFA devices scored regulatory wins since the new year: Biosense Webster inc.’s Varipulse secured approval from the Japanese Ministry of Health Labor and Welfare and Sichaun Jinjiang Electronic Medical Device Technology Co. Ltd. got the nod from China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/704936</guid>
      <pubDate>Wed, 31 Jan 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704936-boston-scis-farapulse-approval-intensifies-pfa-competition</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/FARAPULSE-pulsed-field-ablation-system-31jan24.webp?t=1716240208" type="image/jpeg" medium="image" fileSize="92584">
        <media:title type="plain">FARAPULSE pulsed field ablation system</media:title>
        <media:description type="plain">Boston Scientific Corp.’s Farapulse. Credit: Boston Scientific</media:description>
      </media:content>
    </item>
    <item>
      <title>Boston Scientific aims high with new long-range plan</title>
      <description>
        <![CDATA[At its Investor Day on September 20, Boston Scientific Corp. unveiled an ambitious long-range plan to become “the highest performing med-tech large-cap company” in terms of financial performance, sales growth, EPS, execution and talent retention.” That’s a notable step up from its 2021 goal of being just one of the top performers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/701188</guid>
      <pubDate>Mon, 25 Sep 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/701188-boston-scientific-aims-high-with-new-long-range-plan</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/bsx-revenue-25sept23.webp?t=1695679698" type="image/jpeg" medium="image" fileSize="189817">
        <media:title type="plain">bsx revenue</media:title>
        <media:description type="plain">High growth markets (&amp;gt;7% CAGR): ICTx (cPCI, DCB, SHV), WM, EP, PI (IO, Drug-eluting, Venous), NM (Brain), Endo (ELS, S/U scopes), Urology (Prostate Health)

Moderate growth markets (4-7% CAGR): CRM (Diagnostics, S-ICD), PI (Core Arterial), NM (Pain), Endo (Biliary, GI Cancer &amp;amp; Bleeding), Urology (Stone Mgmt, Prosthetic Urology)

Low growth markets (&amp;lt;4% CAGR): ICTx (DES), CRM (Pacers, Defibrillators)</media:description>
      </media:content>
    </item>
    <item>
      <title>Medtronic stock drops with mixed 2Q report</title>
      <description>
        <![CDATA[Medtronic plc guided investors’ expectations lower for the balance of its fiscal year, citing pummeling from foreign exchange rates, continued delays in elective procedures and ongoing supply chain issues. In response, the stock (NYSE:MDT) dropped from its close at $82.43 on Monday to open at $76.91 Tuesday. The company reported $7.59 billion in revenue for the first half of its fiscal 2023. That represented a 3% drop on a year-over-year basis, missing consensus expectations of $7.7 billion, in part because of a $457 million foreign currency hit.]]>
      </description>
      <guid>http://www.bioworld.com/articles/691816</guid>
      <pubDate>Tue, 22 Nov 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/691816-medtronic-stock-drops-with-mixed-2q-report</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/12-29-Medtronic-operational-hq.webp?t=1640809185" type="image/png" medium="image" fileSize="2134353">
        <media:title type="plain">Medtronic operational headquarter building</media:title>
        <media:description type="plain">Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>Earnings for March 16, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Catalyst.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504614</guid>
      <pubDate>Tue, 16 Mar 2021 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/504614-earnings-for-march-16-2021</link>
    </item>
    <item>
      <title>Earnings for March 9, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Amicus, Eli Lilly, Hutchison China Meditech.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504495</guid>
      <pubDate>Tue, 09 Mar 2021 12:15:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/504495-earnings-for-march-9-2021</link>
    </item>
    <item>
      <title>Earnings for March 8, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Insmed, La Jolla.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504409</guid>
      <pubDate>Mon, 08 Mar 2021 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/504409-earnings-for-march-8-2021</link>
    </item>
    <item>
      <title>Earnings for March 4, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Amryt, Chi-Med, Pharming, Vine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504289</guid>
      <pubDate>Thu, 04 Mar 2021 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/504289-earnings-for-march-4-2021</link>
    </item>
    <item>
      <title>Earnings for March 2, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Amarin, Moderna.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504192</guid>
      <pubDate>Tue, 02 Mar 2021 12:08:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/504192-earnings-for-march-2-2021</link>
    </item>
    <item>
      <title>Earnings for March 2, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Amicus, Sarepta.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504138</guid>
      <pubDate>Tue, 02 Mar 2021 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/504138-earnings-for-march-2-2021</link>
    </item>
    <item>
      <title>Earnings for Feb. 26, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Biomarin, PTC, Radius.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504102</guid>
      <pubDate>Fri, 26 Feb 2021 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/504102-earnings-for-feb-26-2021</link>
    </item>
    <item>
      <title>Earnings for Feb. 25, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Acadia, Agios, Amarin, Coherus, Intercept, Intra-Cellular, Moderna.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504013</guid>
      <pubDate>Thu, 25 Feb 2021 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/504013-earnings-for-feb-25-2021</link>
    </item>
    <item>
      <title>Earnings for Feb. 24, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Halozyme, Jazz, United.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503959</guid>
      <pubDate>Wed, 24 Feb 2021 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503959-earnings-for-feb-24-2021</link>
    </item>
    <item>
      <title>Earnings for Feb. 23, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Clovis, Epizyme.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503819</guid>
      <pubDate>Tue, 23 Feb 2021 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503819-earnings-for-feb-23-2021</link>
    </item>
    <item>
      <title>Earnings for Feb. 18, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Ironwood.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503684</guid>
      <pubDate>Thu, 18 Feb 2021 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503684-earnings-for-feb-18-2021</link>
    </item>
    <item>
      <title>Earnings for Feb. 16, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Antengene, Forus, Karyopharm.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503613</guid>
      <pubDate>Tue, 16 Feb 2021 12:19:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503613-earnings-for-feb-16-2021</link>
    </item>
    <item>
      <title>Earnings for Feb. 16, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: GW.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503565</guid>
      <pubDate>Tue, 16 Feb 2021 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503565-earnings-for-feb-16-2021</link>
    </item>
    <item>
      <title>Immunogen’s earnings bolster the stock while Ultragenyx struggles</title>
      <description>
        <![CDATA[Immunogen Inc. leads a busy earnings season with numbers that pushed the stock (NASDAQ:IMGN) 30.3% higher on Feb. 12. The antibody-drug conjugates developer posted revenues of $132.3 million for 2020 compared to its $82.3 million in revenues for 2019, a 62.2% increase.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503580</guid>
      <pubDate>Fri, 12 Feb 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503580-immunogens-earnings-bolster-the-stock-while-ultragenyx-struggles</link>
    </item>
    <item>
      <title>Earnings for Feb. 11, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Alkermes, Alnylam, Exelixis, Karyopharm, Vanda.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503422</guid>
      <pubDate>Thu, 11 Feb 2021 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503422-earnings-for-feb-11-2021</link>
    </item>
    <item>
      <title>Earnings for Feb. 9, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Amgen.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503360</guid>
      <pubDate>Tue, 09 Feb 2021 12:22:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503360-earnings-for-feb-9-2021</link>
    </item>
    <item>
      <title>Earnings for Feb. 9, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Incyte.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503332</guid>
      <pubDate>Tue, 09 Feb 2021 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503332-earnings-for-feb-9-2021</link>
    </item>
    <item>
      <title>Earnings for Feb. 5, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Alexion, Astrazeneca, Gilead, Neurocrine, Regeneron, Sanofi.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503269</guid>
      <pubDate>Fri, 05 Feb 2021 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503269-earnings-for-feb-5-2021</link>
    </item>
    <item>
      <title>Earnings for Feb. 4, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Acceleron, Alexion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503195</guid>
      <pubDate>Thu, 04 Feb 2021 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503195-earnings-for-feb-4-2021</link>
    </item>
    <item>
      <title>Pfizer expects its COVID-19 vaccine to bring in $15B in 2021</title>
      <description>
        <![CDATA[Pfizer Inc. reported solid earnings for 2020 and said it expects even bigger things this year as the company projects approximately $15 billion in earnings from the COVID-19 vaccine it co-developed with Biontech SE.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503179</guid>
      <pubDate>Wed, 03 Feb 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503179-pfizer-expects-its-covid-19-vaccine-to-bring-in-15b-in-2021</link>
    </item>
    <item>
      <title>Earnings for Feb. 3, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Amgen, Biogen.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503164</guid>
      <pubDate>Wed, 03 Feb 2021 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503164-earnings-for-feb-3-2021</link>
    </item>
    <item>
      <title>Earnings for Feb. 2, 2021</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Vertex.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503111</guid>
      <pubDate>Tue, 02 Feb 2021 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503111-earnings-for-feb-2-2021</link>
    </item>
    <item>
      <title>Pandemic puts pressure on drug sales</title>
      <description>
        <![CDATA[The 39th Annual J.P. Morgan Healthcare Conference was sans Celgene Corp.'s annual tradition of kicking off the conference with preliminary revenue and earnings from the previous year, but plenty of other companies stepped up and offered preliminary results of their own. Unfortunately, some companies continued to face headwinds selling drugs during the pandemic as patients avoided their doctors' offices.]]>
      </description>
      <guid>http://www.bioworld.com/articles/502560</guid>
      <pubDate>Tue, 19 Jan 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/502560-pandemic-puts-pressure-on-drug-sales</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/drug-prices-open-capsule-dollar-sign.webp?t=1588362577" type="image/png" medium="image" fileSize="385556">
        <media:title type="plain">Drug pricing illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Earnings for Nov. 17, 2020</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Nippon Shinyaku, Zogenix.]]>
      </description>
      <guid>http://www.bioworld.com/articles/500255</guid>
      <pubDate>Tue, 17 Nov 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/500255-earnings-for-nov-17-2020</link>
    </item>
    <item>
      <title>Earnings for Nov. 10, 2020</title>
      <description>
        <![CDATA[Quarterly snapshots from biopharma companies with marketed products, including: Beigene.]]>
      </description>
      <guid>http://www.bioworld.com/articles/499973</guid>
      <pubDate>Tue, 10 Nov 2020 12:12:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/499973-earnings-for-nov-10-2020</link>
    </item>
  </channel>
</rss>
